Yield trap — a 13.33% yield the price does not believe. A 13.33% yield on a $2.70 close is the trap signature, not income strength: $0.09 a quarter, $0.36 indicated, after cuts from $0.29 in early 2023 to $0.15 in 2024 and $0.08 in 2025, with the share price down about 47% over the past year. Q2 normalized FFO of $0.15 covers the quarter on paper, but the free-cash-flow payout sits near 218.85% and past-year earnings were negative, so the payout is funded despite, not by, the business's cash generation.
Key risk: Tenant payment and refinancing risk — hospital tenants have failed before, and a $2.40 billion secured refinancing at a 9.25% coupon shows what lenders now charge this balance sheet; one more tenant failure or refinancing step can force another cut.
Changes if: Free cash flow covers the dividend with room to spare and the price recovers toward the dividend's history — until then the yield is compensation for cut risk, not earned income.
- ✗Coverage check: Q2 NFFO of $0.15 covers the $0.09 dividend at about 60%, but the free-cash-flow payout is about 218.85% and trailing earnings were negative at about -$0.06 a share — paper coverage, not cash coverage.
- ✗Trap check — yield vs. total return: 13.33% indicated at $2.70, with the price down about 47% over the past year and the dividend cut from $0.29 to $0.08 across 2023–2025: the yield rose because the price collapsed, the classic trap pattern.
- ✗Dividend growth check: No compounding record — cuts in 2023–2024, a partial step back from $0.08 to $0.09 in late 2025, and no growth streak to underwrite the rate.
What this grade doesn't say: It screens the dividend only — covered, real, compounding. It says nothing about valuation or price: a well-covered payer can still be overpriced, and its price can still fall.